E. Eric Tokat is Co-President of Investment banking at Centerview Partners, a leading independent investment bank with offices in New York, San Francisco, Menlo Park, London and Paris.
Mr. Tokat has been critical in helping to build Centerview into a preeminent advisory firm and positioning it for continued success. As Co-President of Investment Banking, he works with fellow members of Centerview’s senior management in overseeing and implementing the firm’s strategy and continuing to develop its industry-leading client franchises.
Mr. Tokat is a founder of Centerview’s Healthcare practice and has played an instrumental role in establishing the practice as the market leader in strategic advisory. Mr. Tokat has advised on more than 100 transactions over his career exceeding $500 billion in total deal value, including many of the most important, industry-defining life sciences transactions of the past decade. He is a frequent speaker on Healthcare industry trends and has been quoted in leading publications including The Wall Street Journal, The Financial Times, Bloomberg News and STAT News.
Mr. Tokat’s recent life sciences transactions in the last ten years include:
- 2025: $10bn sale of Verona Pharma to Merck; $9.5bn sale of Blueprint Medicines, $1.9bn sale of DrenBio and $600M sale of Vigil Therapeutics to Sanofi; $2.5bn sale of Scorpion Therapeutics, $1.35bn sale of Verve Therapeutics and $1bn sale of SiteOne Therapeutics to Lilly; $2bn sale of Boston Pharmaceuticals and $1.15bn sale of IDRx to GSK; $3.9bn sale of SpringWorks Therapeutics to Merck KGaA, $2.1bn sale of Capstan Therapeutics to Abbvie; sale of Inozyme to Biomarin; sale of Evergreen Theragnostics to Lantheus
- 2024: $3.2bn sale of Morphic to Lilly; $3bn sale of Morphosys and $1.75bn sale of Mariana Oncology to Novartis; $2.5bn sale of Fusion and $950M sale of Amolyt to AstraZeneca; $3bn sale of EyeBio and $680M sale of Harpoon Therapeutics to Merck; $2.2bn sale of Inhibrx to Sanofi with simultaneous spin off of Oncology assets into a new publicly-traded company; $1.4bn sale of Aliada to Abbvie; $1.25bn sale of Numab and $1bn sale of Proteologix to J&J; $1.1bn sale of Jnana to Otsuka; sale of Cardior to Novo Nordisk; sale of Alimera to ANI Pharma; sale of Ironshore Therapeutics to Collegium Pharmaceutical; sale of Chimagen to GSK; Merger between Exscientia and Recursion Pharmaceuticals
- 2023: $11bn sale of Prometheus to Merck, $4bn sale of Rayzebio to BMS, $3.5bn sale of Chinook to Novartis, $3bn sale of Carmot to Roche, $2.9bn sale of ProventionBio to Sanofi, $2bn sale of BellusHealth to GSK, $1.8bn sale of Cincor to AstraZeneca, $1.5bn acquisition of Amryt by Chiesi, $1.4bn sale of Point to Lilly, $1.2bn sale of Gracell to AstraZeneca, $1.2bn sale of VectivBio to Ironwood, $1.2bn sale of Albireo to Ipsen, sale of Emergence to Lilly, sale of Inversago to Novo Nordisk, sale of Decibel to Regeneron, Pfizer’s sale of select rare disease assets to AstraZeneca, sale of LianBio’s Mevacampten China rights to BMS
- 2022: $12.5bn sale of Biohaven to Pfizer with simultaneous spin of Neuroscience assets into a new publicly traded company; Sale of Imago BioSciences to Merck for $1.35bn; Sale of Akouos to Lilly for up to $600M; Sale of Oyster Point Pharma to Viatris for up to $500M; Sale of MiroBio to Gilead for $405M; Sale of ReViral Therapeutics to Pfizer for $525M; Sale of DSJ Antibodies to Abbvie for $255M; Sale of Checkmate Pharmaceuticals to Regeneron for $250M; Sale of Tmunity to Kite Pharma/Gilead
- 2021: Sale of Amunix Pharmaceuticals to Sanofi for $1bn Upfront and $225mm in Milestones; $6.7bn acquisition of Arena Pharmaceuticals by Pfizer; $2.3bn sale of Trillium Therapeutics to Pfizer; Up to $2bn sale of Vividion Therapeutics to Bayer AG; $1.7bn sale of Constellation Pharmaceuticals to Morphosys AG; $1.9bn sale of Pandion Therapeutics to Merck; $4.6bn sale of Cantel Medical to Steris; Sale of Lengo Therapeutics to Blueprint Medicines for up to $465M; Sale of Sanifit to Vifor Pharma for up to €375M; Pfizer’s spin out of select Autoimmune assets and creation of Priovant; $200M investment in Immunovant by Roivant
- 2020: $1bn sale of Prevail Therapeutics to Eli Lilly; $2.75bn sale of VelosBio to Merck; $2.9bn sale of Eidos to BridgeBio; $650M sale of Biospecifics to Endo; Up to $1.75bn sale of exclusive option to acquire Pionyr Immunotherapeutics to Gilead; Merck’s spin off of Organon
- 2019: ArQule's $2.7bn sale to Merck; Synthorx's $2.5bn sale to Sanofi; Achillion's up to $1.2bn sale to Alexion; Ra Pharma's $2.5bn sale to UCB S.A., Exact Sciences’ $2.8bn acquisition of Genomic Health; Peloton Therapeutics’ up to $2.2bn sale to Merck; Spark Therapeutics’ $4.8bn sale to Roche; Ipsen’s up to $1.3bn acquisition of Clementia Pharmaceuticals
- 2018: Merck’s €3.25bn acquisition of Antellia; Syntimmune’s up to $1.2bn sale to Alexion; Pfizer’s consumer JV with GSK; Pfizer’s spin out of CAR-T assets and creation of Allogene; Pfizer’s spin out of Neuroscience assets and creation of Cerevel Therapeutics; Synergy Pharmaceutical’s sale to Bausch Health
- 2017: Kite Pharma’s $12bn sale to Gilead; Valeant’s $1bn sale of Dendreon to Sanpower Group; China Regenerative Medicine’s acquisition of Obagi Medical from Valeant
- 2016: Pfizer’s $14bn acquisition of Medivation and $5bn acquisition of Anacor; Raptor’s $1bn sale to Horizon; Mylan’s $10bn acquisition of Meda
- 2015: Salix’s $16bn sale to Valeant; Dyax’s $6bn sale to Shire; Achillion's up to $1bn WW HCV collaboration with and $225m equity investment by J&J; Dendreon’s sale to Valeant
Mr. Tokat has been involved in numerous educational and charitable causes throughout his career and currently serves on a number of not-for-profit boards, including as: a trustee at the Brookings Institution, a member of the Board of Advisors at the IRC (International Rescue Committee), a member of the Board of Advisors at Columbia University Irving Medical Center and Vagelos College of Physicians and Surgeons, as well as a member of the Board of Advisors of Columbia University School of International and Public Affairs. He is also a member of the Council on Foreign Relations.
Mr. Tokat received his BA from Bogazici University and MIA from Columbia University.